Neos Therapeutics Company Profile (NASDAQ:NEOS)

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics logoNeos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEOS
  • CUSIP: N/A
  • Web:
  • Market Cap: $184.68 million
  • Outstanding Shares: 22,560,000
Average Prices:
  • 50 Day Moving Avg: $7.57
  • 200 Day Moving Avg: $6.90
  • 52 Week Range: $4.85 - $9.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.96
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $12.2 million
  • Price / Sales: 12.20
  • Book Value: $0.56 per share
  • Price / Book: 11.79
  • EBIDTA: ($77,120,000.00)
  • Net Margins: -719.86%
  • Return on Equity: -512.10%
  • Return on Assets: -87.88%
  • Debt-to-Equity Ratio: 4.68%
  • Current Ratio: 2.87%
  • Quick Ratio: 2.66%
  • Average Volume: 573,665 shs.
  • Beta: -0.79
  • Short Ratio: 8.37
Frequently Asked Questions for Neos Therapeutics (NASDAQ:NEOS)

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.07. The company earned $5.63 million during the quarter. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. View Neos Therapeutics' Earnings History.

Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?

2 analysts have issued 1-year price targets for Neos Therapeutics' shares. Their predictions range from $15.00 to $20.00. On average, they anticipate Neos Therapeutics' share price to reach $17.50 in the next year. View Analyst Ratings for Neos Therapeutics.

Who are some of Neos Therapeutics' key competitors?

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the folowing people:

  • Alan Heller, Chairman of the Board
  • Vipin K. Garg Ph.D., President, Chief Executive Officer, Director
  • Richard Eisenstadt, Chief Financial Officer
  • Juergen A. Martens Ph.D., Chief Technology and Operations Officer
  • Dorothy Engelking, Vice President of Regulatory Affairs
  • Thomas P McDonnell, Chief Commercial Officer
  • Beth P. Hecht, Director
  • Paul R. Edick, Non-Executive Director
  • Bryant E. Fong, Non-Executive Director
  • Gregory J. Robitaille, Non-Executive Director

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy Neos Therapeutics stock?

Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of Neos Therapeutics stock can currently be purchased for approximately $6.60.

MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  154
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neos Therapeutics (NASDAQ:NEOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.50 (165.15% upside)

Analysts' Ratings History for Neos Therapeutics (NASDAQ:NEOS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/20/2017BMO Capital MarketsReiterated RatingOutperform$15.00HighView Rating Details
4/5/2017Cowen and CompanyInitiated CoverageOutperform$20.00HighView Rating Details
5/18/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
5/17/2016Royal Bank Of CanadaLower Price TargetOutperform$33.00 -> $29.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$33.00 -> $32.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Neos Therapeutics (NASDAQ:NEOS)
Earnings by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Earnings History by Quarter for Neos Therapeutics (NASDAQ NEOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.94)($0.87)$5.63 millionViewListenView Earnings Details
3/14/2017Q4 2016($1.36)($1.14)$3.50 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.64)($1.61)$1.58 millionViewN/AView Earnings Details
8/11/2016Q2($1.16)($1.65)$1.48 million$1.49 millionViewListenView Earnings Details
5/16/2016Q1($0.87)($0.79)$1.50 million$2.58 millionViewListenView Earnings Details
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
Current Year EPS Consensus Estimate: $-3.17 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS


Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Neos Therapeutics (NASDAQ:NEOS)
Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 33.08%
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2016Bryant FongDirectorBuy1,500$6.54$9,810.00View SEC Filing  
8/25/2016Richard I EisenstadtCFOBuy3,710$6.82$25,302.20View SEC Filing  
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.00View SEC Filing  
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00View SEC Filing  
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.00View SEC Filing  
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.10View SEC Filing  
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.66View SEC Filing  
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.64View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Neos Therapeutics (NASDAQ:NEOS)
Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
DateHeadline logoNeos Therapeutics, Inc. (NASDAQ:NEOS) Expected to Post Earnings of -$0.83 Per Share - July 20 at 12:24 AM logoNeos Looks Attractive With Short And Long Term Catalysts - July 1 at 3:36 AM logoAttention To Details: Neos' ADHD Portfolio - June 27 at 6:53 PM logoBRIEF-Neos Therapeutics announces proposed offering of common stock - June 27 at 6:53 PM logoForm 8-K Neos Therapeutics, Inc. For: Jun 26 - June 27 at 6:53 PM logoNeos Therapeutics Announces Pricing of Underwritten Public Offering of $32.4 Million of Common Stock - June 27 at 6:53 PM logoNeos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.83 Per Share - June 23 at 10:24 PM logoNeos nets second ADHD drug approval - for no-swallow, dissolve pill - June 23 at 7:19 PM logoShire wins U.S. approval for long-acting ADHD drug - June 21 at 5:56 AM logoNeos Therapeutics, Inc. (NEOS) Lifted to "Sell" at ValuEngine - June 20 at 11:40 PM logoNeos Therapeutics Slides Despite FDA Approval - June 20 at 7:53 PM logoShire's long-acting ADHD drug wins U.S. approval - June 20 at 7:53 PM logoNeos Therapeutics, Inc. (NEOS) Receives Outperform Rating from BMO Capital Markets - June 20 at 12:28 PM logoNeos Therapeutics Says ADHD Drug Cotempla XR-ODT Gets FDA Approval - June 20 at 7:45 AM logoNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old - June 19 at 10:53 PM logoNeos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference - June 14 at 9:25 AM logoNeos Therapeutics, Inc. (NEOS) Upgraded to "Buy" at Zacks Investment Research - June 13 at 4:40 PM logoNeos Therapeutics Inc (NEOS) Stock Rating Lowered by Zacks Investment Research - June 10 at 7:26 AM logoBRIEF-Neos Therapeutics enters into first amendment to its existing facility agreement with lenders - June 5 at 7:27 PM logoZacks Investment Research Upgrades Neos Therapeutics Inc (NEOS) to Buy - June 3 at 7:12 AM logoSwiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study - May 31 at 9:46 AM logo Brokerages Anticipate Neos Therapeutics Inc (NEOS) to Post -$0.83 Earnings Per Share - May 30 at 4:24 PM logoNeos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference - May 30 at 7:31 AM logoTwo Red Hot Biotechs With Big Near-term Catalysts Ahead - May 28 at 7:13 PM logoNeos Therapeutics Inc (NEOS) Rating Lowered to Strong Sell at ValuEngine - May 27 at 3:14 PM logoNeos Therapeutics Inc (NEOS) Cut to "Hold" at Zacks Investment Research - May 27 at 7:46 AM logoNeos Therapeutics Inc (NEOS) Lifted to "Hold" at Zacks Investment Research - May 18 at 11:34 PM logoNeos Therapeutics Inc (NEOS) Stock Rating Upgraded by ValuEngine - May 18 at 3:28 PM logoNeos Therapeutics to Present at 2017 UBS Global Healthcare Conference - May 16 at 10:15 AM logoNeos Therapeutics Inc (NEOS) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS - May 10 at 4:56 PM logoNeos Therapeutics Reports First Quarter 2017 Financial Results - May 9 at 11:34 AM logoNeos Therapeutics reports 1Q loss - May 9 at 9:41 AM logoZacks: Analysts Expect Neos Therapeutics Inc (NEOS) Will Post Earnings of -$0.89 Per Share - May 4 at 10:50 PM logoNeos Therapeutics (NEOS) Earns Daily Coverage Optimism Rating of 0.24 - May 3 at 11:18 PM logoNeos Therapeutics to Host First Quarter 2017 Financial Results Conference Call on May 9, 2017 - May 2 at 2:37 PM logoNeos Therapeutics Inc (NEOS) Receives Consensus Rating of "Buy" from Brokerages - May 2 at 9:32 AM logoNeos Therapeutics (NEOS) Earns Daily Media Impact Score of -0.04 - April 27 at 6:24 PM logoNeos Therapeutics (NEOS) Receives Daily Media Sentiment Score of 0.17 - April 24 at 8:48 PM logoNeos Therapeutics (NEOS) Receives News Sentiment Score of 0.28 - April 22 at 12:17 AM logoShort Interest in Neos Therapeutics Inc (NEOS) Rises By 7.5% - April 20 at 5:56 PM logoNeos Therapeutics (NEOS) Receives Media Impact Score of -0.12 - April 17 at 3:58 PM logoNeos Therapeutics (NEOS) Given Daily Media Sentiment Rating of 0.03 - April 14 at 2:52 PM logoZacks: Brokerages Expect Neos Therapeutics Inc (NEOS) Will Announce Earnings of -$0.85 Per Share - April 13 at 8:30 PM logoBloomberg Markets: Dave Wilson’s Stock of the Day for April 5 - April 7 at 11:26 AM logoNeos Therapeutics Inc (NEOS) Receives New Coverage from Analysts at Cowen and Company - April 6 at 12:25 AM logoNeos Therapeutics Inc (NEOS) Receives Average Recommendation of "Buy" from Analysts - April 5 at 2:39 PM logoNeos Therapeutics downgraded by UBS - March 20 at 4:55 PM logoNeos Therapeutics Inc (NEOS) Lowered to “Hold” at Zacks Investment Research - March 18 at 8:46 AM logoNEOS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report - March 15 at 6:58 PM logoNeos Therapeutics Inc (NEOS) Announces Quarterly Earnings Results - March 15 at 10:10 AM



Neos Therapeutics (NEOS) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff